{"title":"Arsenic Trioxide and Acute Promyelocytic Leukemia: A Drug for All Stages of Disease","authors":"Kamran Alimoghaddam","doi":"10.3816/CLK.2008.n.013","DOIUrl":null,"url":null,"abstract":"<div><p>Arsenic trioxide is an older drug that has recently been introduced into new medicine. It is very potent against a specific type of leukemic cell harboring a translocation between chromosomes 15 and 17. It has been demonstrated that this drug is effective against all stages of acute promyelocytic leukemia (APL), including for remission induction of relapsed cases or as first-line treatment. It is also useful in the consolidation/maintenance phase of treatment. Many trials are ongoing to determine the best and optimum schedule for this drug as a single agent or in combination with other drugs. In the future, its indications might extend to other malignancies. In this review, we study the biologic effects of arsenic trioxide on APL cells and the results of clinical trials on the treatment of patients with APL. We will also discuss the toxicity and minimal residual detection during patient follow-up.</p></div>","PeriodicalId":100271,"journal":{"name":"Clinical Leukemia","volume":"2 2","pages":"Pages 107-112"},"PeriodicalIF":0.0000,"publicationDate":"2008-05-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.3816/CLK.2008.n.013","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Leukemia","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1931692512600515","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1
Abstract
Arsenic trioxide is an older drug that has recently been introduced into new medicine. It is very potent against a specific type of leukemic cell harboring a translocation between chromosomes 15 and 17. It has been demonstrated that this drug is effective against all stages of acute promyelocytic leukemia (APL), including for remission induction of relapsed cases or as first-line treatment. It is also useful in the consolidation/maintenance phase of treatment. Many trials are ongoing to determine the best and optimum schedule for this drug as a single agent or in combination with other drugs. In the future, its indications might extend to other malignancies. In this review, we study the biologic effects of arsenic trioxide on APL cells and the results of clinical trials on the treatment of patients with APL. We will also discuss the toxicity and minimal residual detection during patient follow-up.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
